WEGOVY- semaglutide injection, solution
Novo Nordisk


In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of WEGOVY and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY [see Contraindications (4) and Warnings and Precautions (5.1)].


WEGOVY is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of [see Dosage and Administration (2.1)]:

30 kg/m2 or greater (obesity) or
27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

Limitation of Use

WEGOVY contains semaglutide and should not be coadministered with other semaglutide-containing products or with any other GLP-1 receptor agonist.
The safety and effectiveness of WEGOVY in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
WEGOVY has not been studied in patients with a history of pancreatitis [see Warnings and Precautions (5.2)].


2.1 Patient Selection

Select patients for WEGOVY treatment as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management based on their BMI. BMI is calculated by dividing weight (in kilograms) by height (in meters) squared. A chart for determining BMI based on height and weight is provided in Table 1.

Table 1. BMI Conversion Chart
Table 1
(click image for full-size original)

2.2 Important Administration Instructions

Prior to initiation of WEGOVY, train patients on proper injection technique. Refer to the accompanying Instructions for Use for complete administration instructions with illustrations.
Inspect WEGOVY visually prior to each injection. Only use if solution is clear, colorless, and contains no particles.
Administer WEGOVY once weekly, on the same day each week, at any time of day, with or without meals.
Administer WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without dose adjustment.
If one dose is missed and the next scheduled dose is more than 2 days away (48 hours), administer WEGOVY as soon as possible. If one dose is missed and the next scheduled dose is less than 2 days away (48 hours), do not administer the dose. Resume dosing on the regularly scheduled day of the week.
If more than 2 consecutive doses are missed, resume dosing as scheduled or, if needed, reinitiate WEGOVY and follow the dose escalation schedule, which may reduce the occurrence of gastrointestinal symptoms associated with reinitiation of treatment.

2.3 Recommended Dosage

Initiate WEGOVY with a dose of 0.25 mg injected subcutaneously once-weekly and follow the dose escalation schedule in Table 2 to minimize gastrointestinal adverse reactions [see Adverse Reactions (6.1)].

Table 2. Dose Escalation Schedule


Weekly Dose

1 through 4

0.25 mg

Dose escalation

5 through 8

0.5 mg

9 through 12

1 mg

13 through 16

1.7 mg

Week 17 and onward

2.4 mg

Maintenance dose

If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks.
The maintenance dose of WEGOVY is 2.4 mg injected subcutaneously once-weekly.
If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once-weekly, for a maximum of 4 weeks. After 4 weeks, increase WEGOVY to the maintenance 2.4 mg once-weekly. Discontinue WEGOVY if the patient cannot tolerate the 2.4 mg dose.
In patients with type 2 diabetes, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment.


Injection: clear, colorless solution available in 5 pre-filled, disposable, single-dose pens:

Dose per Injection

Total Strength per Total Volume

0.25 mg

0.25 mg / 0.5 mL

0.5 mg

0.5 mg / 0.5 mL

1 mg

1 mg / 0.5 mL

1.7 mg

1.7 mg / 0.75 mL

2.4 mg

2.4 mg / 0.75 mL

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.